• prescription cold sore treatment

TARGETED PRESCRIPTION COLD SORE TREATMENT¹

 

Fewer Recurrences. More Freedom.

Cold sores are a sore subject for many, which is why new Sitavig (acyclovir), 50mg Muco-Adhesive Buccal Tablet is such a breakthrough in the world of prescription cold sore treatment. Sitavig is a single-dose, prescription-strength treatment that may stop cold sores before they start, which means fewer outbreaks and a lot more freedom.¹

Sitavig works by delivering a concentrated dose of prescription cold sore medication that stays localized at the site of viral replication in the mouth. In clinical trials, patients who applied prescription Sitavig within one hour of the first sign of an outbreak experienced significant relief from their cold sore symptoms in just 3.5 days — and completely healed within 5.5 days.1 Plus, on average, patients treated with Sitavig went 105 days longer between cold sore outbreaks compared to patients treated with a placebo.1

The freedom to live your life — with fewer cold sores.¹

Knowledge is freedom when it comes to cold sores. Know your triggers and stop cold sore outbreaks before they happen¹ — so you have the freedom to get on with your life. What will you have more freedom to do with fewer cold sore outbreaks?

 

Additional cold sore resources:

References

  1. Bieber T, Chosidow O, Bodsworth N, Tyring S, Hercogova J, Bloch M, Davis M, Lewis M, Boutolleau D, Attali P and the LIP Study Group. Efficacy and safety of acyclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP): A double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014;13(7):791-798. View study (link will lead you to the JDD site).
Indication & Important Safety Information
INDICATION Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.

IMPORTANT SAFETY INFORMATION Sitavig should not be used in patients with known hypersensitivity to acyclovir, milk protein concentrate, or other components of the product. Sitavig has not been studied in pregnant women or in immunocompromised patients and no interaction studies have been performed. Sitavig’s safety and efficacy have not been established in pediatric patients. Sitavig is a Pregnancy Category B product; therefore it should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is not known if Sitavig is excreted in breast milk; however, systemic absorption is minimal. In a controlled clinical trial Sitavig’s most common side effects (greater than or equal to 1%) were: headache (3%), dizziness (1%), lethargy (1%), gingival (gum) pain (1%), aphthous stomatitis (canker sores) (1%), application site pain (1%), application site irritation (1%), erythema (1%) and rash (1%). In the same trial these side effects ranged from 0%-3% for placebo. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Click here for Full Prescribing Information.